Lawmakers in the US House of Representatives are expected to consider the GENIUS Act soon, while the Senate has shifted to discussing crypto market structure legislation.

Today's health news includes NIH grants reinstated, RFK Jr.'s new vaccine recommendations, and esketamine therapy results.

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe treatment-resistant depression in Scotland but intravenous ketamine has not ...

Esketamine Monotherapy Safe, Effective for TRD: Phase 4 Data Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

For patients with major depressive disorder, duloxetine offers an alternative when other antidepressants are ineffective or cannot be tolerated.